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ABSTRACT
Objective: The purpose of this study was to compare the clinical efficacy and safety of intravenous
trospectomycin to that of cefoxitin plus doxycycline in the treatment of women hospitalized with
acute pelvic inflammatory disease (PID).
Methods: Thirty-nine patients admitted with a clinical diagnosis of an acute PID were enrolled in
this prospective, single-blind study. Patients were treated with either intravenous trospectomycin,
500 mg every 8 h, or intravenous cefoxitin, 2 g every 6 h, plus oral or intravenous doxycycline, 100
mg every 12 h, in a 2:1 ratio. The patients were followed for clinical response and side effects. Both
groups of patients were discharged on oral doxycycline for 10 days. Appropriate cultures were
obtained before starting inpatient treatment, on completion of inpatient treatment, and at 2 follow-
up visits.
Results: The overall success rate for trospectomycin was 95.6% and for cefoxitin/doxycycline was
91.6%. This difference was not statistically significant (P 0.63). Trospectomycin was found to be
effective against Chlamydia trachomatis.
Conclusions: Single-agent therapy with trospectomycin may be as effective as cefoxitin plus doxy-
cycline in the treatment of women hospitalized with acute PID. Infect. Dis. Obstet. Gynecol.
5:215-218, 1997. (C) 1997 Wiley-Liss, Inc.
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cute pelvic inflammatory disease (PID) is a
polymicrobial infection.-4 The most frequent
pathogens involved in this mixed infection include
Neisseria gonorrhoeae, Chlamydia trachomatis, aerobic
organisms such as streptococcal species, entero-
cocci, Escherichia co/i, and anaerobic bacteria such as
Bacteroides spp. and Peptostreptococcus spp. Since
therapy must be instituted before availability of
microbiologic results, empiric treatment with
broad-spectrum antibiotics is recommended as ini-
tial therapy. Cefoxitin is widely used for the treat-
ment of acute PID because of its broad-spectrum
activity. However, cefoxitin is ineffective against C.
trachomatis and hence is often used with doxycy-
cline. There are also recent reports of development
of resistance to cefoxitin by some enterococcal and
staphylococcal species,s
Trospectomycin sulfate is a novel broad-
spectrum aminocyclitol antibiotic with activity
against a majority of aerobes, anaerobes, N. gonor-
rhoeae, and C. trachomatis.6-8 This study was under-
taken to evaluate the safety and clinical efficacy of
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trospectomycin as a single-agent therapy in the
treatment of acute PID. Monotherapy has many
advantages. First, and most important to the pa-
tient and physicians, is the fact that combination
therapy involves the possible toxic effects of two or
more drugs. Furthermore, there is an ease of ad-
ministration with monotherapy. It can be less ex-
pensive because of the savings of not mixing anti-
biotics and using fewer intravenous tubings.
MATERIALS AND METHODS
The clinical protocol of this study was approved by
the Institutional Review Board of Temple Univer-
sity School of Medicine. Thirty-nine consecutive
patients admitted to Temple University Hospital
with a clinical diagnosis of acute PID were enrolled
in this study. The diagnosis of acute PID was
based on the presence of abdominal pain and ten-
derness, uterine tenderness, cervical motion ten-
derness, and adncxal tenderness. An additional re-
quirement was an elevated temperature (>100.4F)
and/or an elevated white cell count (> 10,000/ram3)
and/or an elevated erythrocyte sedimentation rate
(>20 ram/h) and/or the presence of purulent vaginal
discharge.
At the time of admission, the cervix was gently
wiped with a sterile swab and then specimens were
taken from the endocervix and placed on Thayer
Martin medium for N. gonorrhoeae and Shcppard’s
10B broth for C. trachomatis. Endometrial samples
were taken using transcervical aspiration curette
(Pipelle (R), Unimar, Inc., Wilton, CT) under aseptic
conditions and processed for C. trachomatis and N.
gonorrhoeae in similar fashion. In addition, endomc-
trial cultures were also obtained for ellycoplasma
hominis, Ureap/asma urealyticum, facultative aerobes,
and anaerobes. The organisms were isolated and
their susceptibility testing for all 3 antibiotics was
performed using National Committee for Clinical
Laboratory Standards.9,1 Minimum inhibitory con-
centration (MIC) of 64 g/ml or less was considered
susceptible. The laboratory tests included com-
plete blood count with differential count, urinaly-
sis, studies for renal and hepatic functions, sero-
logic test for syphilis, and urine pregnancy test.
Using a simple computer-generated randomiza-
tion table, patients were allocated to trospectomy-
cin vs. cefoxitin plus doxycycline in a 2:1 ratio.
Following randomization, trospectomycin was ad-
ministered intravenously, 500 mg every 8 h, or ce-
TABLE I. Patient characteristics
Cefoxitin/
Trospectomycin doxycycline
Variable (N 26) (N 13)
Age (years) 26.7 + 7.5 26. + 4.6
Weight (Ib) 151 + 42.4 141. + 30.2
Past history of PID 3 2
Past history of sexually
transmitted disease 16 6
Admission white cell count 16.3 + 6.2 16.2 + 6.5
Admission
temperature (F) 101.3 +/- 1.2 101.2 +/- 1.4
Length of stay (days) 5.2 + 0.9 4.8 + 0.7
Mean _+ SD.
foxitin was given at a dosage of 2 g every 6 h along
with 100 mg of doxycycline, orally or intravenously.
The patients were followed daily for temperature,
abdominal tenderness, and pelvic tenderness. A
clinical failure was defined as persistent elevation
of temperature of greater than 100.4F and/or wors-
ening of signs and symptoms of acute PID in a
patient who had received the study medications for
a minimum of 48 h.
The hematologic studies were repeated every
48 h while the patients were hospitalized. The pa-
tients were discharged after a minimum of4 days of
inpatient treatment and had achieved complete
resolution of signs and symptoms of acute PID. All
the cultures were repeated at the time of discharge.
The patients in both groups were given 10 days of
oral doxycycline. Patients received follow-up visits
4-7 days and 21-28 days after the completion of
the outpatient treatment. The laboratory tests were
repeated at the first follow-up visit and cultures
were repeated on both follow-up evaluations.
Statistical analysis was performed using the
Mantel-Haenszel chi-square formula. When a cell
value of less than 5 was encountered, a two-tailed
P-value was obtained by means of the Fisher’s ex-
act test. For continuous variables, a P-value was
calculated through a one-way analysis of variance of
the means. P < 0.05 was considered significant.
RESULTS
Of 39 patients enrolled in the study, 26 received
trospectomycin and 13 received cefoxitin plus
doxycycline. There was no statistical difference be-
tween the 2 groups with respect to age, weight,
admission temperature, and admission white cell
count (Table 1). The length of hospital stay for the
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TABLE 2. Isolates at admission
Trospectomycin Cefoxitin/doxycycline
Organisms Endomet Endocx Endomet Endocx
N. gonorrhoeae 12
C. trachomatis 3
M. hominis 13
U. urealyticum 14
Gram-positive aerobes
Streptococcus spp. 13
Enterococcus spp. 3
Staph. epidermidis 4
Gram-negative aerobes
E. coli 3
Enterobacter sp. 0
Anaerobes
Bacteroides spp. 10
Peptostreptococcus spp. 3
Gardnerella vaginalis 3
17
3
18
20
aEndomet," Endocx,.
trospectomycin group was 5.2 ___
0.9 days, while that
for the cefoxitin/doxycycline group was 4.8 ___
0.7
days. This was not statistically different. Three pa-
tients in the trospectomycin group were omitted
from the study; 2 patients received a non-protocol
antibiotic for a positive syphilis test and patient
had recurrent gonococcal infection. One patient in
the cefoxitin/doxycycline group was omitted be-
cause of recurrent gonococcal infection.
The overall clinical success for trospectomycin
was 95.6% (22 of 23) and for cefoxitin/doxycycline
was 91.6% (11 of 12). This difference was not sta-
tistically significant. One failure in each group re-
sponded to alternative treatment with the combi-
nation of ampicillin, gentamicin, and clindamycin.
Isolates on admission are presented in Table 2.
In general, MICs for trospectomycin were compa-
rable to cefoxitin, except for those to C. trachomatis.
As expected, the chlamydial isolates were sensitive
to trospectomycin and doxycycline, but resistant to
cefoxitin. Despite increasing resistance of organ-
isms usually involved in acute PID to doxycycline,
the pathogens isolated in our series were all sus-
ceptible to this antibiotic.
The overall frequency of adverse events was not
significantly different between the 2 groups. There
were no serious side effects in either group. Minor
side effects included vomiting (1 in the cefoxitin/
doxycycline group and 2 in the trospectomycin
group); indigestion (1 in each group), and headache
(1 in the cefoxitin/doxycycline group and 2 in the
trospectomycin group). There were no clinically
significant drug-related changes in blood urea ni-
trogen, creatinine, or bilirubin. One subject in the
trospectomycin group showed elevation of liver en-
zymes on the day following completion of the in-
patient treatment. These enzymes returned to nor-
mal at the second follow-up visit. There were no
cases of antibiotic-associated colitis.
DISCUSSION
This is the first study to examine the use of tro-
spectomycin in the treatment of acute PID. This
study demonstrates that trospectomycin is as effec-
tive as cefoxitin/doxycycline combination for inpa-
tient treatment of upper genital tract infections.
Selection of appropriate therapy for the treat-
ment of polymicrobial upper genital tract infections
requires an understanding of the spectrum of ac-
tivity of available antimicrobial agents. Trospecto-
mycin is a 6’ propyl analog of spectinomycin with
unique pharmacokinetics and broad spectrum of
activity. It is highly effective against anaerobes,
gram-positive and gram-negative aerobes,6-8 peni-
cillin-sensitive and -resistant N. gonorrhoeae, 11 and
C. trachomatis. 6,1z A single 250 mg intramuscular
injection of trospectomycin has been shown to be
as effective as a single dose of ceftriaxone in the
treatment of uncomplicated gonococcal infection. 11
In vitro studies have demonstrated significant ac-
tivity against C. trachomatis (MIC 3.1-12.5 pg/ml),
which constitutes an important extension over
spectinomycin spectrum.6,e Trospectomycin is
highly effective against M. hominis and at least
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 217TROSPECTOMYCIN INACUTE PID CHATWANI ET AL.
2-fold more active than macrolides and tetracy-
clines against U. urealyticum. 13 Trospectomycin has
a prolonged post-antibacterial effect and a long se-
rum half-life, 2.18 h compared to 0.5-1.0 h for ce-
foxitin.7’14 Trospectomycin exhibits in vitro and in
vivo antimicrobial activity for up to 9 h or longer
after single intravenous or intramuscular injec-
tion. 7,14 Therefore, this antibiotic can be adminis-
tered 2 or 3 times daily. The replacement of an
antibiotic with less frequent dosing can result in a
35% savings in the annual cost of administration of
antibiotics, ls,16 All of the above characteristics
make trospectomycin an ideal initial antibiotic for
the treatment of acute PID.
Since trospectomycin is effective against C. tra-
chomatis, it can be used as a single-agent therapy for
acute PID. The advantages of single-agent therapy
are avoidance of toxic effects of multiple drugs,
fewer allergic reactions, and less drug interactions.
Furthermore, monotherapy is easy to administer
and less expensive, because of savings in terms of
nursing time and pharmacy charges. The adminis-
tration of trospectomycin 3 times a day makes it
even more attractive than cefoxitin.
Even though we discharged the patients on oral
doxycycline after receiving inpatient trospectomy-
cin, results of in vitro microbial susceptibility test-
ing suggest that this may not be necessary. All 3
patients with chlamydial infection had negative
cultures at the time of their discharge. Trospecto-
mycin was well tolerated with few drug-related
side effects.
The results of this preliminary study suggest
that trospectomycin may represent a potential
single-agent therapy for acute PID. A much larger
study is needed to establish the role of trospecto-
mycin as monotherapy for upper genital tract in-
fections, especially with C. trachomatis.
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